Hair care

Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market exposition comprehensive information that help to build business strategists during the forecast 2021-2027.

Which provides an exhaustive analysis of key market trends & dynamics along with market estimates & forecasts covering major geographies/countries on the basis of historical data. Considering Platelet Rich Plasma and Stem Cell Alopecia Treatment revolutions of the cat1 industry which is major factors of growth.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research sources which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Self-Adhesive Labels includes major supplies & Independent Consultants among others.

The report used two methodologies FPNV Positioning Matrix and the Competitive Strategic Window to assess the figures for all segments and competitive marketplace in terms of product satisfaction and business strategy they follow to sustain in the market.

Pharmaceuticals and Healthcare Development

– India has reached out to top American pharma companies seeking investment in the country’s pharmaceutical and medical devices sector
– The Serum Institute of India will invest 240 million pounds in the UK
– The annual change in WPI notified by the government works out to 0.5% for 2020, the drug prices regulator National Pharmaceutical Pricing Authority said.

Market Segmentation

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is segmented on the basis of type, application, end-use industry, and region & country.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Type

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment type, the market is divided into type Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia. Platelet Rich Plasma and Stem Cell Alopecia Treatment market’s sub-segment is expected to hold the largest market share during the forecast period. Increased demand for high-quality industrial valves in the Pharmaceuticals and Healthcare and other industries.

Also to mitigate the risk of contamination is driving the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment at present. The growing concern about the market and industry is expected to boost the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in Pharmaceuticals and Healthcare.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Application

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment application, the market is divided into Hospital, Dermatology Clinic, Other. Platelet Rich Plasma and Stem Cell Alopecia Treatment application valves are one of the most basic and indispensable components of today’s modern technological society. A market segment is expected to hold the largest market share in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

Global Market Scope and Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size

The scope of the report is to provide a 360-degree view of the market by assessing the entire value chain and analyzing the key Platelet Rich Plasma and Stem Cell Alopecia Treatment market trends from 2021 to 2027 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Country Level Analysis

Most of the countries are estimated to emerge as the fastest growing region and hold the largest market share in the global industrial Platelet Rich Plasma and Stem Cell Alopecia Treatment market, mainly due to Growing industry trends of present situations, which cannot be ignored. Geographically, regional insights have been segmented on the basis of North America, Europe, Asia Pacific, South America and The Middle East And Africa region.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment market players identified in the report are listed below

Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen, RepliCel Life Sciences

Market

Some of the other major highlights of the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment report include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market during the forecast period.

COVID-19 Impact Analysis

– The COVID-19 pandemic had a significant impact on the on-trade segment and Industry.
– Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation.
– The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry is expected to stabilize after 2021.
– The liquor industry was not impacted severely due to the pandemic.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Trends

– The report identifies, determines, and forecasts the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
– Industry to Industry Holds Largest Share in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market
– It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
– Demand from Regional / geographical is Expected to Drive the Growth
– Rising Adoption of Market Segments in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Growth
– North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
– It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Platelet

Rich Plasma and Stem Cell Alopecia Treatment Market.

Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market, years considered, and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth are segmented on the basis of market type, application, end-user and region.

Based on Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Based on Application

Hospital
Dermatology Clinic
Other

Regions Covered

Americas
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Chile
Colombia
Rest Of Latin America

Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Rest of Europe

Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Indonesia
Malaysia
Thailand
Philippines,
Vietnam
Rest of Asia-Pacific

The Middle East And Africa
Saudi Arabia
United Arab Emirates
South Africa
Iran
Turkey
Morocco
Nigeria
Algeria
Cameroon
Chad
Congo
Egypt
Kuwait
Rest of LAMEA

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Celluma RESTORE for Hair Loss

Celluma RESTORE for Hair Loss

BioPhotas Announces Celluma RESTORE for Hair Loss

BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced today a major product line extension to the Company’s award-winning Celluma SERIES of Light Therapy Devices.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions. This is the 14th model in the Celluma SERIES.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions.

Commenting on the latest addition to the product line, BioPhotas President and Chief Executive Officer Patrick Johnson said, “It’s great to add a Hair Restoration indication-for-use to our long list of treatment clearances from the FDA. Providing a single device that treats whole body aches and pains, fine lines and wrinkles, and hair loss on the scalp is the ultimate baby-boomer anti-ageing device.

Now the mature individual interested in feeling and looking great, and retaining their youthful appearance, can have a device at home that meets all of their rejuvenating needs.” The Celluma RESTORE is targeted directly at the multi-billion-dollar global health and wellness market, specifically, the non-invasive hair restoration segment of the medical aesthetics industry.

The Celluma RESTORE is non-toxic, non-invasive, and painless. The device is versatile, convenient, and easy-to-use in both a clinical setting or at home. Celluma’s patented, the shape-taking design permits customized placement over the head to effectively deliver light energy and promote hair regrowth.

Additionally, the Celluma RESTORE can be placed anywhere on the body to reduce pain and improve skin health. Measuring 16″ x 8″ overall with a treatment area of 14″ x 6″, the Celluma RESTORE can be stored flat in a drawer for convenience and easy access.

Commenting further on the announcement, Mr Johnson said, “Having just celebrated the 10th anniversary of BioPhotas, it is only appropriate that we receive our 10th indication-for-use clearance from the FDA. The Celluma SERIES now has more regulatory credentials than any other LED device in the world and is legally registered for sale in 78 countries around the globe.

We anticipate that the new RESTORE will be available to our U.S. customers in mid-August. The new device is already slated for MDR Tech File review later this summer and should be available in the E.U. and U.K. in the 4th quarter.”

The Celluma SERIES has also continued its winning ways by adding five new industry awards in the first half of 2021. Celluma Light Therapy was recognized by Les Nouvelles Esthetiques & Spa Magazine with two Best Product awards. Dermascope Magazine also recognized Celluma devices with two Aesthetician’s Choice Awards. And the readers of Skin Deep Magazine awarded Celluma the Reader’s Choice award for Favorite LED Device, making the Celluma SERIES the most award-winning LED device with more than 40 international awards.

Visit www.celluma.com to see the complete line of Celluma devices.

About BioPhotas, Inc.

In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions.

BioPhotas Announces Celluma RESTORE for Hair Loss

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts

Gene Tied to Balding

Gene Tied to Balding

Gene Tied to Balding May Also Raise COVID Risks for Men

It’s long been known that COVID-19 is more fatal for men than women, and new research links some of that excess risk to a gene known to cause a form of hair loss in males.

A U.S. team of researchers first suspected the link when they noticed that men with a common form of hormone-sensitive hair loss, known as androgenetic alopecia, were also more prone to being hospitalized with COVID-19.

“Among hospitalized men with COVID-19, 79% presented with androgenetic alopecia compared to 31%-53% that would be expected in a similarly aged match population,” said researchers led by Dr Andy Goren, chief medical officer at Applied Biology Inc. in Irvine, Calif. They presented their findings May 6 at the virtual spring meeting of the European Academy of Dermatology and Venereology (EADV).

The researchers noted that androgenetic alopecia is caused by the activity of the androgen receptor (AR) gene, which in some men can lead to hair loss. An enzyme called TMPRSS2, the key to COVID-19 infection, is also androgen-sensitive, and might be affected by the AR gene as well, Goren’s group explained.

One key segment on the AR gene appears to affect both COVID-19 severity and the propensity of men to lose their hair due to androgenetic alopecia.

In the new study, the Irvine group conducted a genetic analysis of 65 men hospitalized with COVID-19. They found that men with certain structural differences in the AR gene were more likely to develop severe COVID-19. Speaking in a meeting press release, Goren said the AR gene aberration “could be used as a biomarker to help identify male COVID-19 patients most at risk for ICU admissions.”

He also believes that “the identification of a biomarker connected with the androgen receptor is another piece of evidence highlighting the important role of androgens [male hormones] in COVID-19 disease severity.”

Dr. Teresa Murray Amato is chair of emergency medicine at Long Island Jewish Forest Hills in New York City and has seen many severe cases of COVID-19. She wasn’t connected to the new research, but said it “did show a significant correlation between a higher number of androgen receptors and a higher incidence of ICU admissions for patients infected with COVID-19.”

Amato added, “While the study is small and the exact association is not completely understood, it may show at least one answer to why men were more likely to be admitted to ICU and have overall higher morality with COVID-19 infections.”

According to Amato, more research is needed to determine whether “medications that block androgen receptors will be useful in treating a subset of [COVID-19] patients.”

Because the findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.

Gene Tied to Balding May Also Raise COVID Risks for Men

Source

Recent Posts

MicroRNA That Shows Promise for Hair Regrowth

MicroRNA That Shows Promise for Hair Regrowth

Researchers Identify MicroRNA That Shows Promise for Hair Regrowth

Researchers from North Carolina State University have identified a microRNA (miRNA) that could promote hair regeneration. This miRNA – miR-218-5p – plays an important role in regulating the pathway involved in follicle regeneration and could be a candidate for future drug development.

Hair growth depends on the health of dermal papillae (DP) cells, which regulate the hair follicle growth cycle. Current treatments for hair loss can be costly and ineffective, ranging from invasive surgery to chemical treatments that don’t produce the desired result.

Recent hair loss research indicates that hair follicles don’t disappear where balding occurs, they just shrink. If DP cells could be replenished at those sites, the thinking goes, then the follicles might recover.

A research team led by Ke Cheng, Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at NC State’s College of Veterinary Medicine and professor in the NC State/UNC Joint Department of Biomedical Engineering, cultured DP cells both alone (2D) and in a 3D spheroid environment. A spheroid is a three-dimensional cellular structure that effectively recreates a cell’s natural microenvironment.

In a mouse model of hair regeneration, Cheng looked at how quickly hair regrew on mice treated with 2D cultured DP cells, 3D spheroid-cultured DP cells in a keratin scaffolding, and the commercial hair loss treatment Minoxidil. In a 20-day trial, mice treated with the 3D DP cells had regained 90% of hair coverage at 15 days.

“The 3D cells in a keratin scaffold performed best, as the spheroid mimics the hair microenvironment and the keratin scaffold acts as an anchor to keep them at the site where they are needed,” Cheng says. “But we were also interested in how DP cells regulate the follicle growth process, so we looked at the exosomes, specifically, exosomal miRNAs from that microenvironment.” Exosomes are tiny sacs secreted by cells that play an important role in cell to cell communication. Those sacs contain miRNAs.

MiRNAs are small molecules that regulate gene expression. Cheng and his team measured miRNAs in exosomes derived from both 3D and 2D DP cells. In the 3D DP cell-derived exosomes, they pinpointed miR-218-5p, a miRNA that enhances the molecular pathway responsible for promoting hair follicle growth. They found that increasing miR-218-5p promoted hair follicle growth, while inhibiting it caused the follicles to lose function.

“Cell therapy with the 3D cells could be an effective treatment for baldness, but you have to grow, expand, preserve and inject those cells into the area,” Cheng says. “MiRNAs, on the other hand, can be utilized in small molecule-based drugs. So potentially you could create a cream or lotion that has a similar effect with many fewer problems. Future studies will focus on using just this miRNA to promote hair growth.”

The research appears in Science Advances, and was supported by the National Institutes of Health and the American Heart Association. Cheng is corresponding author. Postdoctoral researcher Shiqi Hu is first author.

-peake-

“Dermal exosomes containing miR-218-5p promote hair regeneration by regulating β-catenin signaling”

DOI: 10.1126/sciadv.aba1685

Authors: Shiqi Hu, Zhenhua Li, Halle Lutz, Teng Su, Ke Cheng, North Carolina State University College of Veterinary Medicine and the NC State/UNC Joint Department of Biomedical Engineering; Ke Huang, Jhon Cores, Phuong-Uyen Cao Dinh, North Carolina State University College of Veterinary Medicine

Published: July 24, in Science Advances

Abstract: The progression in the hair follicle cycle from the telogen to the anagen phase is the key to regulating hair regrowth. Dermal papilla (DP) cells support hair growth and regulate the hair cycle. However, they gradually lose key inductive properties upon culture. DP cells can partially restore their capacity to promote hair regrowth after being subjected to spheroid culture. In this study, results revealed that DP spheroids are effective at inducing the progression of the hair follicle cycle from telogen to anagen compared with just DP cell or minoxidil treatment.

Because of the importance of paracrine signaling in this process, secretome and exosomes were isolated from DP cell culture, and their therapeutic efficacies were investigated. We demonstrated that miR-218-5p was notably up-regulated in DP spheroid–derived exosomes. Western blot and immunofluorescence imaging were used to demonstrate that DP spheroid–derived exosomes down-regulated the secreted frizzled-related protein 2 and up-regulated β-catenin, promoting the development of hair follicles.

Researchers Identify MicroRNA That Shows Promise for Hair Regrowth

Source

Recent Posts

Alopecia Areata- Market Insight

Alopecia Areata- Market Insight

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Alopecia Areata Market

DelveInsight’s “Alopecia Areata – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alopecia Areata market report provides current treatment practices, emerging drugs, Alopecia Areata market share of the individual therapies, current and forecasted Alopecia Areata market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alopecia Areata treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Alopecia Areata Disease Understanding and Treatment Algorithm

The DelveInsight Alopecia Areata market report gives a thorough understanding of the Alopecia Areata by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Alopecia Areata.

Treatment

It covers the details of conventional and current medical therapies available in the Alopecia Areata market for the treatment of the condition. It also provides Alopecia Areata treatment algorithms and guidelines in the United States, Europe, and Japan.

Alopecia Areata Epidemiology 

The Alopecia Areata epidemiology division provides insights about historical and current Alopecia Areata patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted Alopecia Areata epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Alopecia Areata Epidemiology

The epidemiology segment also provides the Alopecia Areata epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Alopecia Areata Drug Chapters

The drug chapter segment of the Alopecia Areata report encloses the detailed analysis of Alopecia Areata marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Alopecia Areata clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Alopecia Areata treatment.

Alopecia Areata Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Alopecia Areata treatment.

Alopecia Areata Market Outlook

The Alopecia Areata market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Alopecia Areata market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia Areata market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Alopecia Areata market in 7MM.

The United States Market Outlook

This section provides the total Alopecia Areata market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Alopecia Areata market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Alopecia Areata market size and market size by therapies in Japan is also mentioned.

Alopecia Areata Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alopecia Areata market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alopecia Areata Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alopecia Areata key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Alopecia Areata emerging therapies.

Reimbursement Scenario in Alopecia Areata

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Alopecia Areata domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Alopecia Areata market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alopecia Areata Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Alopecia Areata, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Alopecia Areata epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Alopecia Areata is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Alopecia Areata market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alopecia Areata market

Report Highlights

  • In the coming years, the Alopecia Areata market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia Areata R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Alopecia Areata. The launch of emerging therapies will significantly impact the Alopecia Areata market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Alopecia Areata
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alopecia Areata Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Alopecia Areata Pipeline Analysis
  • Alopecia Areata Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alopecia Areata Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Alopecia Areata Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Alopecia Areata Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Alopecia Areata market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Alopecia Areata total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Alopecia Areata market size during the forecast period (2017-2030)?
  • At what CAGR, the Alopecia Areata market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Alopecia Areata?
  • What is the historical Alopecia Areata patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Alopecia Areata in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alopecia Areata?
  • Out of all 7MM countries, which country would have the highest prevalent population of Alopecia Areata during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Alopecia Areata treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Alopecia Areata in the USA, Europe, and Japan?
  • What are the Alopecia Areata marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Alopecia Areata?
  • How many therapies are developed by each company for Alopecia Areata treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Alopecia Areata treatment?
  • What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Alopecia Areata therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alopecia Areata and their status?
  • What are the key designations that have been granted for the emerging therapies for Alopecia Areata?
  • What are the global historical and forecasted market of Alopecia Areata?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Source

Recent Posts

Aesthetics Treatments for Body Improvement

Aesthetics Treatments for Body Improvement

ABM Launches Three Medical Procedures Aesthetics Treatments for Body Improvement

ABM Medical Clinic & Cosmetics, a top-rated clinic for body improvements and facial aesthetics, is proud to announce the addition of three new aesthetic medical procedures. The new body rejuvenation treatments include PRP (Platelet-Rich Plasma) Facial, PRP Therapy for Hair Loss, and Vampire Facial.

Our PRP Facial cosmetic procedure helps tighten the skin and quickens the healing process. Whether wrinkles, age spots, scarring, or hyperpigmentation, our team of board-certified physicians uses a minimally invasive treatment to remove scars, improve skin tone and texture, boost collagen and elastin, and rejuvenate the skin.

We combine both traditional micro needling and modern collagen induction therapy to improve effects and achieve faster results. Our PRP facial procedure is proven to be safe with no chance for allergic reactions because the plasma comes from your own body.

In addition, ABM Medical Clinic & Cosmetic is happy to introduce an innovative hair loss treatment.

Our PRP Hair Loss medical procedure is a product of years of consistently exploring the best options for hair loss solutions. This three-step medical hair restoration procedure uses PRP to trigger healthy hair growth in dying hair follicles.

It also increases the thickness of the hair shaft, helping you revitalize natural hair. Our hair restoration strategy is for women and men seeking the best alternative to hair transplant surgery by appropriately fixing hair loss.

We have also added a nonsurgical cosmetic procedure called Vampire Facial to help men and women offset ageing effects like hollowed-out skin, crow’s feet, bumps, and certain skin deformities. Our Vampire Facial clinical procedure uses cellular therapy to rejuvenate the skin and provide a youthful, natural, and healthy appearance without the need for plastic surgery. It is a non-invasive cosmetic procedure that requires only topical anaesthesia.

We are committed to providing you with the healthiest skin and body, keeping you in the best physical state regardless of age. For more information about our process and to book a free consultation:

ABM Launches Three Medical Procedures Aesthetics Treatments for Body Improvement

Source

Recent Posts

Anti-dandruff Agent Additive Market

Anti-dandruff Agent Additive Market

Global Anti-dandruff Agent Additive Market Insights and Forecast to 2027

Market Analysis and Insights: Global Anti-dandruff Agent Additive Market

The global Anti-dandruff Agent Additive market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

Global Anti-dandruff Agent Additive Scope and Segment

Anti-dandruff Agent Additive market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-dandruff Agent Additive market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2016-2027.

The following manufacturers are covered in this report:

Clariant AG

Aurora Chemical

Spec Chem Group

Kumar Organic

Chemspec Chemicals

3C Pharmchem

Somu Group

Kolon Life Science

Regen Chemical

Symrise

Tinci Materials

Seqens SAS

Merck KGaA

Plater Group

Gaopeng Pharmaceutical

Kavya Pharma

Fengchen Technology

Xi’an Taicheng Chem

Anti-dandruff Agent Additive Breakdown Data by Type

Piroctone Olamine

Climbazole

Slaicylic Acid

Ketoconazole

Coal Tar

Selenium Sulfide

Other

Anti-dandruff Agent Additive Breakdown Data by Application

Personal Care

Pharmaceutical

Regional and Country-level Analysis

The Anti-dandruff Agent Additive market is analysed and market size information is provided by regions (countries).

The key regions covered in the Anti-dandruff Agent Additive market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

The report includes a country-wise and region-wise market size for the period 2016-2027. It also includes market size and forecast by Type, and Application segment in terms of production capacity, price and revenue for the period 2016-2027.

Global Anti-dandruff Agent Additive Market Insights and Forecast to 2027

Source

Recent Posts

Hair Products Cause Hair Loss

Hair Products Cause Hair Loss

Johnson & Johnson Hair Products Cause Hair Loss, Lawsuit Claims

A class-action lawsuit has been filed against Johnson & Johnson with the claim that the company’s OGX hair care products cause significant hair loss.

The products are sold at major national retailers, including Target, Ulta, CVS, Walmart, and Walgreens. Johnson & Johnson shampoos, conditioners, and some hair oils are among the products named in the lawsuit.

The plaintiff, Larissa Whipple, an Illinois woman, cites the ingredient DMDM hydantoin as the main concern. DMDM hydantoin is a preservative and antimicrobial agent sometimes found in hair care products. It’s considered a “formaldehyde donor,” meaning it releases a small amount of formaldehyde overtime to keep the product fresh.

But formaldehyde donors like this one have been linked to allergies, rashes, hair loss, and cancer. The Department of Health and Human Services’ National Toxicology Program has said formaldehyde is known to cause cancer.

The lawsuit says that the company may have violated consumer protection laws by advertising the products containing this ingredient to people who want healthy hair.

“Johnson & Johnson made a number of affirmative misrepresentations … that the products ‘deeply nourish’, ‘gently cleanse,’ and ‘repair hair.’ However, the products’ formula contains an ingredient, or combination of ingredients, that has caused Plaintiff and thousands of consumers to experience hair loss and/or scalp irritation,” the lawsuit says.

Johnson & Johnson says all their ingredients are carefully selected and are listed on the products’ label. The company stated that none of their new products contains DMDM hydantoin and they have not launched any new hair products with this ingredient in several years.

“We carefully select ingredients to ensure the safety and performance of our products,” Johnson & Johnson said in a statement to WebMD. “Some of our existing products contain a small amount of DMDM hydantoin, which is used to prevent mould from developing while the product is in the shower. Every preservative used in our products must clear our rigorous safety assessment process.”

In August 2012, Johnson & Johnson announced it would remove DMDM hydantoin and other similar ingredients from their products by 2015. However, the lawsuit says that is a “broken promise.”

“Johnson & Johnson did in fact remove DMDM hydantoin from existing consumer products at that time,” the lawsuit says. “However, when Johnson & Johnson acquired Vogue International, including their line of OGX products, Johnson & Johnson failed to change the ingredient profile of the products that did not maintain the same standards for consumer safety.”

In the preservatives section of Johnson & Johnson’s safety and care commitment website, the company claims DMDM hydantoin does not meet their safety standards, but further down the page they say they use DMDM hydantoin in products when other preservatives are incompatible with other ingredients in a formula.

Dermatologist Shani Francis, MD, says hair product manufacturers should be striving to create a positive experience for their customers.

“Hair breakage and texture changes are important clues to pay attention to regarding overall hair health. We should always seek out products to enhance our hair care experience,” Francis says. “Having a great understanding of your individual hair needs is most important to avoid problems.”

DMDM hydantoin is listed by the FDA as one of the preservatives found to cause the most allergic reactions from the use of cosmetic products. The FDA requires certain products to list ingredients, but some ingredients may not be specifically identified and instead listed as “fragrance” or “perfume.”

Francis says an important thing to remember is that there is no “one size fits all” for hair care products and seeking out products with a company history of strong customer experience is a good way to look for new products.

“For ingredients, water-based products are generally a good place to start. Aloe vera high in the ingredient list suggests a more acidic pH. Glycerin also is a humectant that can help naturally add moisture to the hair,” Francis says. “Ultimately, balance is most important. Often[times], too much of a good thing is not a good thing. Additionally, if you have an underlying medical, scalp or skin condition, you could have a unique situation and should seek the help of a board-certified dermatologist.”

Johnson & Johnson Hair Products Cause Hair Loss, Lawsuit Claims

Source

Recent Posts